- Home
- Companies
- LimFlow, Inc.
- Articles
LimFlow, Inc. articles
Keep your eyes on the prize but don’t get overwhelmed with the long road ahead. Never forget the problem you are trying to solve and the people you are trying to heal, but also know that you don’t have to solve it all today. Resetting every morning by remembering who you are trying to help will give you the energy to fight and bring others to your side. Someone once said, “You don’t have to have the courage for the entire jour
Dave Philistin
Background. As the most advanced stage of peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI) is associated with a high risk of lower-limb loss and mortality. Percutaneous deep vein arterialization (pDVA) is a promising new treatment alternative for CLTI patients who cannot be treated with conventional revascularization techniques. Our study objective was to explore the potential cost-effectiveness of treatment with the LimF
Jan B. Pietzsch;Merle Ederhof;Benjamin P. Geisler;Peter A. Schneider
What interested you in LimFlow, and how did you get involved in the PROMISE I trial?
Dr. Clair: Practicing vascular surgery, where a number of patients are evaluated for chronic limb-threatening ischemia (CLTI), you are guaranteed to have patients who are not candidates for percutaneous or surgical revascularization. These patients often have arterial systems open or identifiable to the ankle, with little to no flow in the foot, or what has been term
Daniel Clair;Mehdi H. Shishehbor;Jorge Martínez Trabal;Michiel Schreve;Miguel Montero-Baker;Brian Lepow;Roberto Ferraresi;Michiel Schreve
The increasing incidence of peripheral artery disease (PAD) is occurring globally as populations age and rates of diabetes, obesity, and renal disease increase.1-3 Although most of these patients have no symptoms, when the disease progresses to its most advanced form, chronic limb-threatening ischemia (CLTI), there is a significant risk for limb loss. Despite the fact that our revascularization options have improved over the last 20 years, a significant portion of patients with CLT
Daniel Clair;Roberto Ferraresi;Andrej Schmidt;Steven Kum